Shire Pharmaceuticals has received FDA approval for a labeling change for its once-daily Attention Deficit Hyperactivity Disorder (ADHD) treatment Vyvanse (lisdexamfetamine dimesylate capsules). This change to the prescribing information will include supplemental data that demonstrated significant ADHD symptom control in children aged 6-12 from the first time point measured (1.5 hours) through 13 hours post dose. This labeling change is based on a 13-hour analog classroom study that demonstrated improvements in behavior, inattention, and math test scores in children aged 6-12 from the first time point measured (1.5 hours) through the last time point assessed (13 hours) post dose.

Vyvanase is indicated for the treatment of ADHD in both adults and children.

For more information call (800) 828-2088 or visit www.vyvanse.com.